Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

David Margolin, MD, PhD

Dr Margolin is senior vice-president, clinical and translational medicine at Cerevance, Inc.

Articles by David Margolin, MD, PhD

Treating Cognitive Impairment in Patients with Schizophrenia

ByDavid Margolin, MD, PhD

November 20th 2020

A recent drug trial yields encouraging results.

Latest Updated Articles

Treating Cognitive Impairment in Patients with Schizophrenia
Published: November 20th 2020 | Updated:

Trending on Psychiatric Times

Recognizing the Neuropsychiatric Symptoms of Huntington Disease

Trust, Compassion, and Care: A World Mental Health Day Reflection

New ECNP Poster Data on Adjunctive Lumateperone for Major Depressive Disorder

Poll: How Can We Individually and Collectively Improve Our Mental Health?

© 2025 MJH Life Sciences^®

All rights reserved.